Sponsored content brought to you by

Foresight Diagnostics Logo

IPM: What is the objective of and rationale behind Allogene Therapeutics’ ALPHA3 trial?

Zach Roberts,
Zach Roberts, MD, PhD
EVP, R&D, and CMO
Allogene Therapeutics

Zach Roberts: The pivotal Phase II ALPHA3 trial is designed to prevent relapse in patients with large B-cell lymphoma (LBCL) who remain at high risk after completing first-line (1L) chemoimmunotherapy. Approximately 30% of LBCL patients who initially respond to standard regimens such as R-CHOP eventually relapse, often within a year.1 The current standard of care (SOC) after 1L treatment has been simply to “watch and wait” to see if the disease relapses. The ALPHA3 trial aims to move beyond this standard, toward a proactive intervention in the subset of patients most likely to relapse.

Using the investigational Foresight CLARITY™ MRD assay to identify these high-risk patients, the study randomizes MRD-positive individuals to either observation or a single infusion of our investigational allogeneic anti-CD19 CAR T product, cemacabtagene ansegedleucel (cema-cel). Cema-cel is a one-time, “off-the-shelf” treatment that is being investigated for administration immediately upon discovery of residual disease following six cycles of R-CHOP or other chemoimmunotherapy, positioning it to become a “7th cycle” of 1L treatment. The goal is to demonstrate that early intervention at a point of very low disease burden can improve event-free survival and potentially be curative, which could completely reshape treatment for LBCL by addressing relapse before it occurs.

IPM: What is minimal residual disease, and why is it especially useful in this setting of LBCL and consolidation therapy?

Minimal residual disease, or MRD, refers to a small amount of cancer that remains after treatment that is often undetectable by standard imaging. Testing for MRD by methods other than imaging helps determine whether therapy has fully eradicated the disease or if microscopic disease persists that could lead to relapse. MRD can be detected in several ways, including high-resolution flow cytometry and assessments of circulating tumor DNA (ctDNA) in plasma. In the case of Foresight CLARITY, the assay utilizes ctDNA as a highly sensitive molecular marker of residual disease.

Foresight CLARITY has demonstrated over 85% clinical sensitivity for relapse detection and over 90% clinical specificity for confirming remission at the end of therapy in B-cell lymphoma.2 In December 2024, ctDNA-based MRD detection was incorporated into clinical practice guidelines for diffuse large B-cell lymphoma to confirm equivocal PET-positive results at the end of 1L treatment when a biopsy is not feasible.3

In the ALPHA3 trial, MRD testing allows us to identify patients with residual ctDNA and a high risk of relapse despite post-treatment scans indicating remission. This enables earlier therapeutic intervention and supports a personalized consolidation approach to potentially improve long-term outcomes.

IPM: What is unique or different about this trial design, particularly in terms of the allogeneic CAR T approach and the MRD-driven patient selection?

ALPHA3 stands out for several reasons. First, it challenges the current standard of care by intervening with CAR T before clinical relapse, when disease burden is low and patients are more likely to respond to treatment.4 Additionally, because CAR T toxicity has been tied to disease burden at the time of infusion, treatment of MRD-only disease may lead to comparatively less toxicity. By moving treatment into this earlier phase, ALPHA3 aims to harness the full potential of CAR T to achieve deeper and more durable responses.

Second, the study uniquely combines ultrasensitive MRD detection with cema-cel, an “off-the-shelf” CAR T product. Because cema-cel is manufactured from healthy donors well in advance of clinical need, patients who are MRD+ after 1L therapy can immediately receive treatment with CAR T cells without the need for referral for autologous CAR T therapy. As an allogeneic, off-the-shelf CAR T option, cema-cel is intended to enable rapid, scalable, and greater access to CAR T therapy across both academic and community centers. Additionally, providing treatment only to those patients who test MRD+, this precision-guided strategy increases the probability that only patients who need more treatment remain in remission after 1L treatment receive it.

Together, these innovations could transform how LBCL is managed by shifting CAR T from a later-line option to a proactive, potentially curative intervention designed to prevent relapse before it occurs. If successful, ALPHA3 could redefine when and for whom CAR T is delivered, changing treatment paradigms and bringing us closer to curing more patients in the frontline setting.

 

References

  1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620
  2. Roschewski M, Kurtz DM, Westin JR, et al. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. J Clin Oncol. Published online August 13, 2025. doi:10.1200/JCO-25-01534
  3. www.nccn.org
  4. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640-654. doi:10.1056/NEJMoa2116133

 

Foresight CLARITY™ is for investigational use and is not approved by the FDA.

Cemacabtagene ansegedleucel is investigational and is not FDA approved. This article discusses an ongoing clinical trial sponsored by Allogene Therapeutics that has not yet reached its prescribed endpoints for analysis. No efficacy or safety data are included. The content is to describe the study design for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. To learn more about ALPHA3, visit www.allogene.com/alpha3.

 

Foresight Diagnostics QR Code

 

To learn more about Foresight CLARITY, visit www.foresight-dx.com.